Senolytics

Senolytics has been studied in 2,068 papers since 2006: 31 trials and 63 observational studies in people, 750 in animals, 245 in cells, 934 reviews; 575 in the past year. The newest story, Nov 16, 2026: “Protein levels alter drug sensitivity in lab-grown human cells”.

Intervention

2,068 papers study it789 more mention it2,628 findingsUpdated

Research on it is growing 35% faster than aging research as a whole: 684 papers in the latest year counted

More supplements

88 new papers in 30 daysSee all 2,791 papers on senolytics

At a glance

Fisetin extends yeast lifespan and reduces senescence in human cells across independent labs, but a study in naturally aging female mice shows no clear survival or physical-function effect. A human trial reports reduced senescence and increased MASH resolution with dasatinib–quercetin. Dasatinib–quercetin increases demyelination in mice; 3 of 22 aging trials have developer sponsorship.

2,628 findings in 1,146 papers from 2007 to 2026, 141 of them since April 2026

Independent labs found the same change in cells, worms or flies, mice and people. 328 independent labs in 42 countries; 25 trials, 25 about aging, 1 with no results posted.

“the difference between UBX1325 and sham in mean change to week 48 in best corrected visual acuity was 5.6 more ETDRS letters (95% confidence interval, -1.5 to 12.7)”
Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular EdemaNEJM evidence2025doi:10.1056/evidoa2400009

111 of its findings point the other way.

Cells, worms or flies, mice and humans: replicated by independent labs.
  • 328 independent labs in 42 countries
  • 111 findings against
  • 25 trials, 25 about aging, 1 with no results posted
  • Funders: National Institutes of Health and others
  • 209 of 2,182 findings with company ties
  • 4 of 25 trials sponsored by its developers
  • Human trial30
  • Humans62
  • Animals715
  • Model organisms12
  • Cells213
  • In silico28

23 studies gave senolytics to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on serious adverse eventsNo serious adverse events in either group; one mild diarrhea episode in each group

up: Increases DLCOcMedian change at days 90 and 180: +1.36 and +0.09 mL/min/mmHg with fisetin versus +0.13 and −1.84 with placebo

down: Decreases systolic blood pressureMedian change −15 mmHg with fisetin versus +7 mmHg with placebo at day 180

Randomized trial180 days10 peopleadultsCVID-associated GLILD; fisetin versus placeboAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, Nov 1, 2026

up: Increases MASH resolutionRR 7.41, 95% CI 1.06 to 51.64

down: Decreases NAFLD Activity Scoremedian [IQR]: −1 [−2 to −1] versus −1 [−1 to 0]

Randomized trial21 weeks31 peopleBothaged 18–70 yearsParticipants with biopsy-proven fibrotic MASHNature metabolism, Oct 1, 2026

down: Decreases GLB1 expression

down: Decreases CDKN2A expression

down: Decreases MIF expression

Randomized trial45 days40 people>55 yearsMidlife adults; Older adults; Both dosing regimensPreprints.org, Jul 22, 2026

up: Improves endothelial function+41% flow-mediated dilation (3.9±0.4% to 5.5±0.5%)

down: Decreases mitoROS bioactivity~-10%

down: Decreases CXCL12-5%

Randomized trialintermittent (2, 3-day dosing periods separated by 14 days)22 peopleBoth71±1 yrsOlder adults; Postmenopausal women; ex vivo: human aortic endothelial cells exposed to 10% participant serumPhysiology, May 1, 2026

down: Decreases plasma inflammatory markers

up: Increases central nervous systemdetected in CSF in 80% (range 0.281–0.536 ng/mL)

up: Increases cerebrospinal fluid IL-6

Trial12 weeks5 peopleBothmean 72 ± 4 yearsOlder adults; SToMP trial; similar trend in STAMINAGSA 2025 abstract, Dec 31, 2025

What did mouse lifespan tests of senolytics find?

NIA ITP

The NIA Interventions Testing Program ran 3 arms from 2015 to 2018; the change in median lifespan ran from −5% to +9%.

What did other lifespan studies of senolytics find?

DrugAge

DrugAge records 4 results from 4 papers: 2 in mice, 1 in D. melanogaster and 1 in S. cerevisiae. Average lifespan is the mean or the median, as each paper reports it.

What did studies of senolytics find?

525

Studies of senolytics measured 525 outcomes; the most studied are cellular senescence (71 studies), inflammation (27) and senescent cells (19).

Cellular senescence

downin mice27downin reviews17downin human cells12downin rats5+7−80%

71 studies
  1. Dasatinib + quercetin decreases cellular senescence in humans (measured by single-nucleus RNA sequencing).

    “Single-nucleus RNA sequencing demonstrates decreased senescence and fibrotic gene signatures and reduced fibrogenic cell populations in the D + Q group.”

    Human trialmeasured by single-nucleus RNA sequencing

    Dasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial

    Nature metabolism

  2. Dasatinib + quercetin decreases cellular senescence in humans (NES −1.4).

    “Overall, senolytic treatment led to a significant decreased expression of senescence gene sets in the D + Q group.”

    Human trial21 weeks

    Dasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial

    Nature metabolism

  3. Fisetin decreases cellular senescence in humans (Cdkn1a -12%; Lmnb1 +16%).

    “expression of Cdkn1a was reduced (P< 0.05) by 12% and expression of Lmnb1 increased (P=0.06) by 16% in PBMCs collected after fisetin but not placebo”

    Human trialperipheral blood mononuclear cell2 mg/kg/day

    Intermittent fisetin treatment improves vascular endothelial function and suppresses cellular senescence in older adults: role of reduced mitochondria-related oxidative stress

    Physiology

  4. Dasatinib + quercetin decreases cellular senescence in mice (naturally aged comparison group).

    “Chronic D + Q, exercise, or both, significantly lowered the proportion of p16+, p21+, and γ-H2AX+ cardiomyocytes and interstitial cells”

    Animalsnaturally aged comparison groupheart9 months

    Exercise or drugs improved heart function in aging mice

    Aging cell

  5. Dasatinib + quercetin decreases cellular senescence in CAP-exposed mice; reductions in β-galactosidase activity and SASP gene expression.

    “treatment with the senolytics Dasatinib and Quercetin (DQ), which eliminate senescent cells, was effective in reversing the CAP-induced senescence”

    Animalsin CAP-exposed mice; reductions in β-galactosidase activity and SASP gene expressionperipheral blood mononuclear cells; endothelial progenitor cells

    Drug pair limited pollution-induced vessel changes in mice

    Cardiovascular toxicology

  6. Dasatinib + quercetin decreases cellular senescence in aged animals.

    “Increased cerebrovascular senescence in aged animals was diminished by D+Q”

    Animalsin aged animalscerebral vasculature

    Senolytic Treatment Triggered by Carotid Occlusion Confers Protection Against Later Acute Ischemic Stroke in Aged Rats

    Aging and disease

  7. Fisetin decreases cellular senescence.

    “exerts senolytic activity by selectively eliminating senescent cells”

    Review

    Natural Bioactive Compounds Targeting Key Hallmarks of Aging: Functional Food Potential of Spermidine, Fisetin, Berberine, and Urolithin A

    Nutrients

  8. Senolytics decrease cellular senescence in silico (Simulated coupled cellular–matrix system with illustrative parameters) (Cellular state s∗ = 0.651 to s∗ = 0.125).

    “a single senolytic course flips the cellular state from the senescentfixed point (s∗ = 0.651) back to the healthy one (s∗ = 0.125)”

    In silicoSimulated coupled cellular–matrix system with illustrative parametersAbove a critical dose (D50 ≈ 0.97; units not stated)single course

    Reversing Cellular Senescence and Extracellular Matrix Degeneration: A Multiscale Model of Senolytic Intervention and Verifiable Recovery Predictions

    Zenodo (CERN European Organization for Nuclear Research)Preprint

  9. Piperlongumine decreases cellular senescence in human cells.

    “piperlongumine as a rejuvenating agent in human cells”

    Cellsin human cells

    Gene activity clock tracks relative age across human tissues

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)

  10. Senolytics decrease cellular senescence.

    “intermittent administration of senolytics has been associated with the clearance of senescent cells in endothelial, myocardial, and adipose lineages”

    Reviewintermittent administration

    Senolytics and the modulation of cellular senescence: Potential impacts on the prevention of cardiovascular and metabolic diseases

    RECIMA21 - Revista Científica Multidisciplinar

All 73

More on Cellular senescence

Inflammation

downin mice11downin reviews8downin humans2no changein mice2+4

27 studies
  1. Dasatinib + quercetin decreases inflammation in humans.

    “Transcriptomic analysis of RNA isolated from PBMC samples revealed baseline to post-treatment downregulation of seven of the 19 inflammatory related genes included in the CTRA transcriptomic stress profile.”

    Human trialthree monthsn = 4

    Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer's disease

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

  2. Navitoclax decreases inflammation in mouse cells.

    “Navitoclax-loaded nCVTs retained senolytic activity and reduced inflammatory signaling and fibrotic activation in vitro.”

    CellsnCVT-loaded

    Drug-filled particles reduced liver fat buildup in mice

    Journal of controlled release : official journal of the Controlled Release Society

  3. Fisetin decreases inflammation (reviewed preclinical findings).

    “Early findings in animal models and in human cell lines suggest that fisetin has the potential to mitigate age-related diseases by targeting chronic inflammation”

    Reviewreviewed preclinical findings

    Clinical Translation of Fisetin for Age-Related Diseases: Current Evidence and Future Opportunities

    Nutrients

  4. Fisetin decreases inflammation in vitro and in animal models (cited background).

    “Fisetin is a naturally occurring flavonoid with anti-inflammatory, antioxidant and senolytic effects in vitro and in animal models”

    Reviewin vitro and in animal models (cited background)

    Low-Dose Fisetin Supplementation and Its Association With Chronic Inflammation in Middle-Aged and Older Adults: Study Protocol for a Triple-Blind, Randomised, Placebo-Controlled Trial

    Basic & clinical pharmacology & toxicology

  5. Senolytics decrease inflammation in animal models of TBI.

    “therapeutically targeting of senescent cells through administration of senolytic drugs in animal models leads to attenuated neuroinflammation and neurodegeneration in the injured brain”

    Reviewin animal models of TBIbrain

    Cellular senescence and senolytic therapy in traumatic brain injury

    Frontiers in neuroscience

  6. Senolytics decrease inflammation.

    “show promise in preclinical models by mitigating inflammation, restoring macrophage function, and stabilizing plaques”

    Review

    Macrophage senescence and programmed cell death in atherosclerosis: Mechanisms, cross-talk, and emerging therapeutic strategies

    Ageing research reviews

  7. Dasatinib + quercetin decreases inflammation in mice (D-galactose-induced aging model).

    “senolytics significantly reduced intracellular lipid accumulation and subsequent neuroinflammation”

    AnimalsD-galactose-induced aging modelastrocytes

    Senolytics ameliorate cognitive decline in D-galactose-induced aging mice by inhibiting astrocytic cholesterol accumulation

    Mechanisms of ageing and development

  8. Fisetin decreases inflammation.

    “exhibits diverse pharmacological activities including antioxidant, anti-inflammatory, anti-apoptotic, and anti-aging effects”

    Review

    Role of Fisetin in the Mammalian Reproductive System

    Veterinary sciences

  9. Senolytics decrease inflammation in aged mice and mice with MASLD.

    “senolytic treatment targeting senescent macrophages reduced liver inflammation and steatosis in both aged mice and mice with metabolic dysfunction-associated steatotic liver disease.”

    Animalsin aged mice and mice with MASLDliver

    p21⁺TREM2⁺ senescent macrophages fuel inflammaging and metabolic dysfunction-associated steatotic liver disease

    Nature aging

  10. Navitoclax decreases inflammation in mice (aged mice infected with influenza).

    “ABT-263 treatment significantly reduced lung inflammation in aged mice”

    Animalsaged mice infected with influenzalung

    Senolytic Treatment Reduces Acute and Chronic Lung Inflammation in an Aged Mouse Model of Influenza

    Aging cell

All 27

More on Inflammation

Senescent cells

downin reviews11downin mice3downin human cells2downin humans1+2−50% reduction

19 studies
  1. Senolytics decrease senescent cells.

    “senolytics, which selectively eliminate senescent cells by targeting their pro-survival mechanisms”

    Review

    Senotherapeutics: emerging pharmacological strategies for targeting cellular senescence

    International Journal of Veterinary Sciences and Animal Husbandry

  2. Senolytics decrease senescent cells.

    “Consequently, the exploration of senolytic therapies aimed at eliminating senescent cells has gained considerable momentum.”

    Review

    Closing the gap in aging science: unlocking the potential of nanoparticles in senescence therapy

    Biogerontology

  3. Senolytics decrease senescent cells.

    “Senolytic agents such as quercetin, fisetin, and procyanidin C1 selectively eliminate senescent cells”

    Review

    Molecular Mechanisms of Cellular Senescence and Targeted Intervention with Natural Bioactive Compounds

    Journal of Dermatologic Science and Cosmetic Technology

  4. Navitoclax decreases senescent cells in M. abscessus cells.

    “the senolytic drug Navitoclax selectively eradicated senescent cells”

    Cells

    Chronic infection triggers senescence in mouse immune cells

    Nature communications

  5. Senolytics decrease senescent cells (preclinical).

    “Preclinical interventions demonstrate that inflammaging is modifiable through senolytics, which selectively eliminate senescent cells”

    Reviewpreclinical

    Inflammaging: Experimental Insights and Translational Advances

    European journal of immunology

  6. Piperlongumine decreases senescent cells in human cells (OA patient-derived cells).

    “In human OA MCs and CCs, PL reduced senescent cell numbers and enhanced glycosaminoglycan production.”

    CellsOA patient-derived cellsmeniscus and cartilage

    Piperlongumine slowed knee osteoarthritis progression in rats

    Biochemical and biophysical research communications

  7. Senolytics decrease senescent cells.

    “Immune-mediated clearance and senolytic drugs can reduce senescent cell burden”

    Review

    Tissue turnover and rejuvenation through mechanics

    Frontiers in cell and developmental biology

  8. Senolytics decrease senescent cells.

    “senolytics, which selectively eliminate senescent cells”

    Review

    Senotherapeutics: Emerging pharmacological strategies to target cellular senescence

    Advances in Translational Research

  9. Senolytics decrease senescent cells in humans.

    “while reducing inflammatory processes and decreasing the number of senescent cells in a human body”

    Review

    Modulating The Epigenetic Clock, Senolytic Therapies for Human Longevity: Age Tissue Regeneration, Synergistic Effect of Nad+ Precursors and Telomerase, Human Age Enhancement

    Journal of Pharmaceutical Research and Integrated Medical Sciences

  10. Dasatinib + quercetin decreases senescent cells.

    “senolytics (e.g., Dasatinib and Quercetin), which clear senescent cells”

    Review

    A Review of Telomere Biology and Therapeutic Strategies

    Oxford Journal of Student Scholarship

All 19

More on Senescent cells

Senescence-associated secretory phenotype (SASP)

downin mice8downin human cells4downin rats2downin cells1+2

17 studies
  1. Senolytics decrease senescence-associated secretory phenotype (SASP) in human cells.

    “In aged donor tissue, prolonged senolytic-associated treatment attenuated inflammatory and remodeling pathways and reduced senescence-associated secretory factors, including IL-6 and MMP-1”

    Cellsskin3 weeks

    Long-term human skin platform models chronic inflammation and senolytic treatments

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)

  2. Dasatinib + quercetin decreases senescence-associated secretory phenotype (SASP) in human fetal lung explants exposed to cannabinoids and nicotine.

    “The addition of senolytics, Dasatinib and Quercetin (D + Q), reduced the senescence-associated secretory phenotype (SASP), such as IL-6, IL-8, M-CSF, MCP-3, MIP-1β, TNFα, MIP-3β, and TSLP”

    Cellsin human fetal lung explants exposed to cannabinoids and nicotinelung

    Cannabis compounds and nicotine alter fetal lung cultures

    Pediatric research

  3. Fisetin decreases senescence-associated secretory phenotype (SASP) in mice (doxorubicin-treated mice).

    “Fisetin mitigated excess vascular cell senescence and the SASP in young mice administered doxorubicin”

    Animalsdoxorubicin-treated miceintermittent oral supplementation100 mg/kg/day

    Fisetin Supplementation Attenuates Premature Vascular Aging Induced by Doxorubicin via Suppression of Cellular Senescence and Mitochondrial Oxidative Stress

    Aging cell

  4. Dasatinib + quercetin decreases senescence-associated secretory phenotype (SASP) in cells.

    “Reduces senescence-associated secretory phenotype (SASP) factors including IL6, TNF-α, and MMPs”

    Cells

    Senolytic therapy targeting CDKN2A/TP53/SASP pathway with dasatinib-quercetin

    Zenodo (CERN European Organization for Nuclear Research)Preprint

  5. Fisetin decreases senescence-associated secretory phenotype (SASP) in humans (preliminary human studies).

    “Preliminary human studies involving FOXO4-axis modulators, such as high-dose fisetin, show a reduction in the senescence-associated secretory phenotype (SASP)”

    Reviewpreliminary human studieshigh-dose

    Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline

    Naunyn-Schmiedeberg's archives of pharmacology

  6. Dasatinib + quercetin decreases senescence-associated secretory phenotype (SASP) in cyclophosphamide-induced ovarian injury.

    “DQ therapy effectively mitigated CY-induced damage by clearing senescent cells and reducing SASP secretion.”

    Animalsin cyclophosphamide-induced ovarian injuryovaryfemales

    Senolytics alleviate cyclophosphamide-induced premature ovarian insufficiency by eliminating senescent cells

    European journal of histochemistry : EJH

  7. Dasatinib + quercetin decreases senescence-associated secretory phenotype (SASP) in rats after single 30 Gy right-lung irradiation.

    “suppressed multiple senescence-associated secretory phenotype (SASP) factors”

    Animalsafter single 30 Gy right-lung irradiationlung

    Dasatinib and quercetin mitigate radiation-induced lung injury by eliminating senescent cells in a rat model

    Frontiers in pharmacology

  8. Dasatinib + quercetin decreases senescence-associated secretory phenotype (SASP) in rats (aged rats with rotator cuff tear repair).

    “a significant decrease in the gene expression of senescence markers (p21 and p16) and senescence-associated secretory phenotype factors (IL-6, IL-1β, and MMP-3)”

    Animalsaged rats with rotator cuff tear repairsupraspinatus-humerus complex12 weeks after repairn = 24

    Senolytic Combination of Dasatinib and Quercetin Promotes Tendon-to-Bone Healing by Mitigating Age-Related Senescence in Rats

    The American journal of sports medicine

  9. Procyanidin C1 decreases senescence-associated secretory phenotype (SASP) (Early or low-dose phase; selected NFκB-driven SASP components).

    “an early or lowdose phase in which PCC1 attenuates selected NFκB–driven SASP components while stabilizing redox and bioenergetic homeostasis”

    ReviewEarly or low-dose phase; selected NFκB-driven SASP componentslow dose

    Procyanidin C1: A Natural Dual‑Mode Senotherapeutic for Pan‑Organ Senescence Modulation and Clearance

    Preprints.orgPreprint

  10. Procyanidin C1 inhibits senescence-associated secretory phenotype (SASP) in mice (diabetic wounds in mice).

    “By modulating the NF-κB signaling axis, PCC1 administration effectively downregulated senescence-associated secretory phenotype components”

    Animalsdiabetic wounds in mice

    Targeted elimination of senescent cells by ProcyanidinC1 improves diabetic wound healing and restores skin quality

    Free radical biology & medicine

All 17

More on Senescence-associated secretory phenotype (SASP)

Apoptosis

upin reviews8upin human cells3upin mice2upin mouse cells1

14 studies
  1. Dasatinib + quercetin increases apoptosis in human cells (residual senescence-like cell population after β-ionone-mediated OR51E2 activation).

    “dasatinib plus quercetin (DQ), which reduced senescence-associated markers and increased apoptosis.”

    Cellsresidual senescence-like cell population after β-ionone-mediated OR51E2 activationcolorectal cancer cells

    Human colorectal cancer cells become more vulnerable to two drugs

    Aging and disease

  2. Senolytics induce apoptosis.

    “senolytics, which induce SC apoptosis”

    Review

    Is there a role for senotherapeutics in the treatment of giant cell arteritis?

    Ageing research reviews

  3. Senolytics induce apoptosis.

    “Senolytics selectively induces programmed apoptosis in SnCs by antagonizing senescent cell anti-apoptotic pathways.”

    Review

    Cleaning, Chasing and Calming: Promising Paradigms of Senotherapy in Aging-Related Diseases

    International journal of biological sciences

  4. Senolytics induce apoptosis in senescent cells, by disrupting anti-apoptotic pathways and inhibiting PI3K/AKT/mTOR.

    “these agents disrupt anti-apoptotic pathways (SCAPs) and inhibit the PI3K/AKT/mTOR axis, restoring sensitivity to apoptosis”

    Reviewin senescent cells, by disrupting anti-apoptotic pathways and inhibiting PI3K/AKT/mTOR

    The Emerging Role of Senolytics as a Next-Generation Strategy Against Glioma Recurrence: A Narrative Review

    Cancers

  5. Procyanidin C1 induces apoptosis in vitro, in senescent cells (>50 μM required).

    “the in vitro induction of apoptosis in senescent cells typically requires high micromolar concentrations (>50 μM)”

    Reviewin vitro, in senescent cells>50 μM

    Translational Potential and Pharmacokinetic Challenges of Procyanidin C1 as a Next-Generation Senotherapeutic Agent

    Preprints.orgPreprint

  6. Senolytics increase apoptosis in mice (combined with senogenic therapy).

    “while promoting apoptosis across diverse in vivo models”

    Reviewcombined with senogenic therapy

    Senogenic-senolytic treatment strategies enhance tumor control and can improve survival in murine cancer models: a systematic review

    BMC cancer

  7. FOXO4-DRI induces apoptosis in senescent endothelial cells.

    “FOXO4-DRI prevents the binding of FOXO4 to P53, facilitating the phosphorylated P53 nuclear exclusion, which subsequently trigger BAX and cleaved caspase-3, leading to the apoptosis of senescent cells.”

    Cellsin senescent endothelial cells

    FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway

    Frontiers in bioengineering and biotechnology

  8. Fisetin induces apoptosis in senescent cells.

    “selectively activating pro-apoptotic pathways in senescent cells”

    Reviewin senescent cells

    Mechanistic Analysis of Fisetin in Liver Diseases and Its Potential Therapeutic Application in IFALD-A Review of In Vitro and In Vivo Studies

    Nutrients

  9. Senolytics induce apoptosis.

    “senolytics, which selectively trigger apoptosis in SnCs”

    Review

    Heterogeneity of Cellular Senescence, Senotyping, and Targeting by Senolytics and Senomorphics in Lung Diseases

    International journal of molecular sciences

  10. Senolytics induce apoptosis.

    “senolytics, which selectively induce their apoptosis”

    Reviewsenescent cells

    Targeting Senescence: A Review of Senolytics and Senomorphics in Anti-Aging Interventions

    Biomolecules

All 14

More on Apoptosis

Cognitive function

upin mice4no changein rats2upin reviews2upin M. models1+1

10 studies
  1. Dasatinib + quercetin improves cognitive function in mice (TDP-43 Q331K mice).

    “we obtained robust target engagement, rescued cognitive impairment, restored motor unit function, and ameliorated muscle strength and fiber pathology.”

    AnimalsTDP-43 Q331K mice

    Two drugs improved thinking and muscle function in mice

    Amyotrophic lateral sclerosis & frontotemporal degeneration

  2. Dasatinib + quercetin improves cognitive function in mice (D-galactose-induced aging model).

    “administering D + Q results in significant improvements in cognitive performance and a decrease in cellular senescence”

    AnimalsD-galactose-induced aging model

    Senolytics ameliorate cognitive decline in D-galactose-induced aging mice by inhibiting astrocytic cholesterol accumulation

    Mechanisms of ageing and development

  3. FOXO4-DRI improves cognitive function in M. models.

    “administering FOXO4-DRI decreases the accumulation of senescent cells, restores cerebral blood flow and the integrity of the blood-brain barrier (BBB), reverses hippocampal atrophy, and enhances cognitive function.”

    Reviewbrain

    Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline

    Naunyn-Schmiedeberg's archives of pharmacology

  4. Dasatinib + quercetin improves cognitive function in mice after high-fat diet.

    “This intervention effectively restored cognitive function and synaptic protein expression.”

    Animalsafter high-fat diet

    Senolytic therapy ameliorates high-fat diet-induced hippocampal senescence and cognitive decline in mice

    Experimental neurology

  5. Senolytics improve cognitive function (preclinical models of AD).

    “Senolytics, which selectively eliminate senescent cells, have demonstrated benefit in multiple preclinical models of AD, including decreased neuroinflammation, improvement in neuronal function and cognitive performance.”

    Reviewpreclinical models of AD

    Evaluating senescence-targeted approaches in Alzheimer's Disease: What we know and what lies ahead

    Ageing research reviews

  6. Dasatinib + quercetin showed no clear effect on cognitive function in rats.

    “Cognitive function did not differ significantly among groups.”

    Animalsfemales

    Senolytic treatment with Quercetin and Dasatinib mitigates decline in cardiac function and links heart remodeling to cognitive performance in adult Dahl Salt‐Sensitive Female Rats

    AAIC 2025 abstract

  7. Senolytics improve cognitive function in preclinical models.

    “Senolytics selectively eliminate senescent cells and improve cognition in preclinical models”

    Reviewin preclinical models

    Senescence in Aging and Alzheimer's Disease

    Aging and disease

  8. ABT-737 improves cognitive function in LPS-treated mice.

    “This treatment also restored reduced excitatory synaptic transmission, impaired long-term potentiation, and cognitive function in the model.”

    Animalsin LPS-treated mice

    Senescent Microglia Mediate Neuroinflammation-Induced Cognitive Dysfunction by Selective Elimination of Excitatory Synapses in the Hippocampal CA1

    Aging cell

  9. Senolytics improve cognitive function in rodent models of AD.

    “Senolytics clear senescent cells, reduce inflammation, and rescue cognition.”

    Reviewin rodent models of AD

    Autophagy and Cellular Senescence in Alzheimer's Disease: Key Drivers of Neurodegeneration

    CNS neuroscience & therapeutics

  10. Dasatinib + quercetin showed no clear effect on cognitive function in hypercaloric diet-fed rats.

    “D + Q treatment failed to prevent cognitive deficits”

    Animalsin hypercaloric diet-fed rats5 mg/kg and 50 mg/kg respectively, monthly12 to 14 monthsfemales

    "Senotherapy as a multitarget intervention in chronic obesity: Modulation of senescence, neuroinflammation, dysbiosis, and synaptic integrity in middle-aged female Wistar rats"

    Experimental neurology

Senescent cell burden

downin mice5downin reviews2downin A. model1downin human cells1

9 studies
  1. Senolytics decrease senescent cell burden in mice (genetic and pharmacological senolysis in aged mice).

    “Both, genetic and pharmacological senolytic interventions reduced senescent-cell burden and decreased immune cell accumulation in aged kidneys.”

    Animalsgenetic and pharmacological senolysis in aged micekidney

    Insights Into the Interplay Between the Senescent Cells and Immune Cells

    Aging cell

  2. Senolytics decrease senescent cell burden (experimental models and ex vivo tissues).

    “senolytic agents show efficacy in reducing the burden of senescent cells in experimental models and ex vivo tissues”

    Reviewexperimental models and ex vivo tissues

    Cutaneous Cellular Senescence: Inhibitors of Senolytics

    Nursing Edição Brasileira

  3. Dasatinib + quercetin decreases senescent cell burden in A. model after ACL transection.

    “Clearance of senescent cells using the senolytic dasatinib and quercetin (D + Q)”

    Animalsafter ACL transectionskeletal muscle

    Drugs reduce muscle wasting and cartilage damage in mice

    Function (Oxford, England)

  4. Senolytics decrease senescent cell burden in mice following disuse.

    “Senolytic treatment reduced overall senescent cell burden, attenuated macrophage accumulation, and restored muscle mass and function in aged mice following disuse.”

    Animalsfollowing disuseskeletal muscle

    Targeting senescent cells restores muscle recovery in old mice

    Science advances

  5. Senolytics decrease senescent cell burden (atherosclerosis).

    “Preclinical studies indicate that senolytics diminish the burden of senescent cells”

    Reviewatherosclerosisatherosclerotic plaque

    Pharmacological targeting of the senescence-associated secretory phenotype in atherosclerosis: therapeutic potential of senolytics and senomorphics

    Naunyn-Schmiedeberg's archives of pharmacology

  6. Dasatinib + quercetin decreases senescent cell burden in mice after high-fat diet.

    “treatment with the senolytic cocktail dasatinib plus quercetin significantly reduced senescent cell burden”

    Animalsafter high-fat diethippocampus

    Senolytic therapy ameliorates high-fat diet-induced hippocampal senescence and cognitive decline in mice

    Experimental neurology

  7. Dasatinib + quercetin decreases senescent cell burden in mice during PTH treatment.

    “Co-administration of the senolytic agents dasatinib and quercetin during PTH treatment reduced senescent cell burden”

    Animalsduring PTH treatment

    Senescent Cells Involved in Deterioration of Bone Microstructure by High-Frequency Parathyroid Hormone 1-34 Administration and Bone Loss

    Aging cell

  8. Navitoclax decreases senescent cell burden in human cells (replicative senescent HUVECs).

    “Both compounds effectively reduced senescent cell burden”

    Cellsreplicative senescent HUVECs1.0 μM

    Senolytic therapy increases replicative capacity by eliminating senescent endothelial cells

    Experimental gerontology

  9. Dasatinib + quercetin decreases senescent cell burden in mice (surgery-induced, in aged mice).

    “Intermittent treatment of the mice with the senolytic drugs dasatinib and quercetin (D/Q) showed a significant reduction in surgery-induced senescent cell burden.”

    Animalssurgery-induced, in aged micehippocampus

    Depletion of senescent cells improves surgery-induced neuroinflammation in aged mice

    PNAS nexus

More on Senescent cell burden

Healthspan

upin reviews6upin mice1upin rodents1+30%

8 studies
  1. Senolytics improve healthspan.

    “selective elimination can improve health span, establishing senescence as both a pathogenic mechanism and a therapeutic target in systemic aging”

    Review

    Rethinking Senescence Hallmarks in the Brain: Lessons From Peripheral Tissues and Challenges in Defining Neuronal Senescence

    Aging cell

  2. Dasatinib + quercetin improves healthspan.

    “better health from drug combos like dasatinib plus quercetin”

    Review

    Toward Cellular Immortality: A Biotechnological Perspective on Radical Human Longevity

    International Journal For Multidisciplinary Research

  3. Dasatinib + quercetin improves healthspan in mice (+30%).

    “Mayo Clinic Kirkland 2015 D+Q senolytic +30% mouse healthspan”

    Review

    ITU and Developmental Biology: A Single-Axiom View of Zygote-to-Adult Cell Expansion, Waddington Landscape, Yamanaka iPSC, Hox Colinearity, Morphogen Gradients, Turing Patterns, Organoids, Regeneration, Aging Hallmarks, and Teratology — Block B 4/?

    Zenodo (CERN European Organization for Nuclear Research)Preprint

  4. Senolytics improve healthspan.

    “offering a potential avenue to enhance healthspan”

    Review

    SENOLYTICS – A DISCOVERY THAT COULD TRANSFORM THE COURSE OF AGING AND CHRONIC DISEASES

    International Journal of Innovative Technologies in Social Science

  5. Senolytics improve healthspan (pre-clinical).

    “senolytics—agents that selectively eliminate senescent cells—demonstrate compelling pre-clinical efficacy in extending health-span”

    Reviewpre-clinical

    clinical translation: senolytics and anti-aging

    Preprint

  6. Senolytics improve healthspan in rodents (senescent cell clearance).

    “their clearance leads to improvements in healthspan and lifespan”

    Reviewsenescent cell clearance

    Translating Senolytics From Mice to Humans

    GSA 2025 abstract

  7. Senolytics improve healthspan.

    “aimed at reducing the burden of senescent cells, mitigating inflammaging and extending healthspan”

    Review

    From Senescent Cells to Systemic Inflammation: The Role of Inflammaging in Age-Related Diseases and Kidney Dysfunction

    Cells

  8. Senolytics improve healthspan.

    “Emerging strategies such as epigenetic reprogramming, gene editing, stem cell therapy, and senolytic drugs show immense promise in extending health spans”

    Review

    Age reprogramming: Innovations and ethical considerations for prolonged longevity (Review)

    Biomedical reports

Physical function

no changein mice2upin reviews2upin mice1

5 studies
  1. Senolytics improve physical function in mice (NAD-deficient ANDY mice).

    “Senolytic treatment partially improved functional decline without restoring NAD.”

    AnimalsNAD-deficient ANDY mice

    Vitamin B3 withdrawal disrupted multiple body systems in mice

    Nature communications

  2. Fisetin showed no clear effect on physical function in mice (naturally aging mice grouped by chronological or biological age).

    “no improvements in endurance, strength, or most contractile outcomes when grouping mice by chronological or biological age.”

    Animalsnaturally aging mice grouped by chronological or biological agesupplemented chow500 ppm12 weeksfemalesn = 99

    Dietary fisetin does not improve physical function or muscle contractility in naturally aging female mice

    Translational Exercise Biomedicine

  3. Senolytics improve physical function in preclinical studies.

    “targeting senescent cells with senolytics can reduce inflammation and improve physical function”

    Reviewin preclinical studies

    A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial design

    Therapeutic advances in medical oncology

  4. Senolytics improve physical function.

    “senolytics can improve cardiovascular function, metabolism, and physical performance”

    Review

    SENOLYTICS – A DISCOVERY THAT COULD TRANSFORM THE COURSE OF AGING AND CHRONIC DISEASES

    International Journal of Innovative Technologies in Social Science

  5. Fisetin showed no clear effect on physical function in young mice.

    “Fisetin had no effects in young mice.”

    Animalsin young mice

    Intermittent Supplementation With Fisetin Improves Physical Function and Decreases Cellular Senescence in Skeletal Muscle With Aging: A Comparison to Genetic Clearance of Senescent Cells and Synthetic Senolytic Approaches

    Aging cell

Bone loss

downin mice3downin animals1downin reviews1

5 studies
  1. Senolytics prevent bone loss in mice.

    “Clearance of senescent cells prevents age-related bone loss in mice”

    Reviewbone

    Cellular senescence and the SASP in skeletal ageing: convergent mechanisms of progressive bone loss in osteoporosis

    Biogerontology

  2. Senolytics decrease bone loss in preclinical studies.

    “Preclinical studies using pharmacological and genetic clearance of senescent cells and suppression of the senescence associated proinflammatory signature lays the foundation for exploring these strategies as therapeutic interventions that could mitigate BMAd and associated bone loss.”

    Reviewin preclinical studies

    Bone Marrow Skeletal Stem Cell Dysfunction: Adipocytes during skeletal aging and senescence

    Current opinion in endocrine and metabolic research

  3. Dasatinib + quercetin prevents bone loss (chemotherapy-induced bone loss).

    “treatment with the senolytic combination dasatinib and quercetin (D + Q) selectively eliminates senescent CAR cells and BMAds, effectively preventing chemotherapy-induced bone loss”

    Animalschemotherapy-induced bone lossbone

    Chemotherapy-induced adipo-lineage cell senescence drives bone loss

    Nature communications

  4. Navitoclax decreases bone loss in mice (periodontitis).

    “Senolytics via Navitoclax successfully alleviated inflammation and bone loss in periodontitis”

    Animalsperiodontitis

    CD81⁺ senescent-like fibroblasts exaggerate inflammation and activate neutrophils via C3/C3aR1 axis in periodontitis

    eLife

  5. Senolytics decrease bone loss in mice given senescent BMAd transplants.

    “which is reversed by senolytic treatment”

    Animalsin mice given senescent BMAd transplantsbone marrow

    Serum amyloid P secreted by bone marrow adipocytes drives skeletal amyloidosis

    Nature aging

TNF-alpha

downin human cells1downin humans1

2 studies
  1. Dasatinib + quercetin decreases TNF-alpha in humans (-3.0% (95% CI -13.0 to 7.1), non-significant).

    “Mean percent change in tumour necrosis factor-alpha (TNF-α), a key product of the senescence-associated secretory phenotype (SASP), non-significantly decreased following DQ by -3.0% (95% CI: -13.0, 7.1)”

    Human trial

    A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer's disease

    EBioMedicine

  2. Dasatinib + quercetin decreases TNF-alpha in humans.

    “The mean percent reduction in TNF-α was significantly different (p = 0.04) than the mean percent change in the Biomarker Control group (mean percent change = 16.8, 95% CI: −1.7, 35.4).”

    Human trial12 weeksn = 12

    A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer's disease

    EBioMedicine

  3. Dasatinib + quercetin decreases TNF-alpha in Caco-2/THP1 co-culture model of IBD.

    “lower levels of the pro-inflammatory markers TNF-α, CXCL-10, and MCP-1”

    Cellsin Caco-2/THP1 co-culture model of IBDintestinal epithelium

    Effects of senotherapeutics on gut microbiome dysbiosis and intestinal inflammation in Crohn's disease: A pilot study

    Translational research : the journal of laboratory and clinical medicine

More on TNF-alpha

Serious adverse events

no changein humans2

2 studies
  1. Fisetin showed no clear effect on serious adverse events in humans (CVID-associated GLILD; fisetin versus placebo) (No serious adverse events in either group; one mild diarrhea episode in each group).

    “No serious adverse events occurred, and one mild diarrhea episode occurred in each group.”

    Human trialCVID-associated GLILD; fisetin versus placebo20 mg/kg180 daysn = 10

    Fisetin pilot trial hints at benefits in lung disease

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

  2. Dasatinib + quercetin showed no clear effect on serious adverse events in humans.

    “There were no serious adverse events related to the intervention.”

    Human trial

    A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer's disease

    EBioMedicine

Endothelial function

upin humans1upin mice1

2 studies
  1. Fisetin improves endothelial function in humans (+41% flow-mediated dilation (3.9±0.4% to 5.5±0.5%)).

    “FMDBA was improved by 41% with fisetin (pre: 3.9±0.4%, post: 5.5±0.5%, P< 0.0001), but unchanged with placebo”

    Human trialBioFisetinbrachial artery2 mg/kg/dayintermittent (2, 3-day dosing periods separated by 14 days)n = 22

    Intermittent fisetin treatment improves vascular endothelial function and suppresses cellular senescence in older adults: role of reduced mitochondria-related oxidative stress

    Physiology

  2. Navitoclax improves endothelial function in mice (PGRN−/− mice).

    “Pharmacological clearance of senescent cells improved endothelial function but increased vascular contractility in PGRN−/− mice.”

    AnimalsPGRN−/− micevascular endothelium

    Progranulin deficiency aggravates aging-induced vascular injury

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

Montreal Cognitive Assessment score

no changein humans1upin humans1

1 study
  1. Dasatinib + quercetin showed no clear effect on montreal Cognitive Assessment score in humans (+1.0 point (95% CI -0.7 to 2.7), non-significant).

    “Mean Montreal Cognitive Assessment (MoCA) scores non-significantly increased following DQ by 1.0 point (95% CI: -0.7, 2.7)”

    Human trial

    A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer's disease

    EBioMedicine

  2. Dasatinib + quercetin improves montreal Cognitive Assessment score in participants with lowest baseline MoCA scores (+2.0 points (95% CI 0.1 to 4.0)).

    “but increased significantly by 2.0 points (95% CI: 0.1, 4.0) in those with lowest baseline MoCA scores”

    Human trialin participants with lowest baseline MoCA scores

    A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer's disease

    EBioMedicine

Frailty score

no changein humans1

1 study
  1. Fisetin showed no clear effect on frailty score in humans (CVID-associated GLILD; within fisetin group) (Median score unchanged with fisetin; increased by 2 points with placebo).

    “Median frailty score remained unchanged with fisetin but increased by 2 points with placebo.”

    Human trialCVID-associated GLILD; within fisetin group20 mg/kg on days 0, 1, 28, and 29n = 10

    Fisetin pilot trial hints at benefits in lung disease

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

All 525

What is senolytics linked with?

12

Studies link senolytics with 12 measures, among them skeletal response, atrial fibrillation and immune response.

Skeletal response

upin reviews1

1 study
  1. Senolytics are associated with skeletal response (early human senolytic data).

    “early human senolytic data suggest that skeletal response may depend on baseline senescent-cell burden”

    Reviewearly human senolytic data

    Future directions of osteoanabolic therapies in osteoporosis: Integrating current anabolic agents and emerging senescence-targeted strategies

    Best practice & research. Clinical rheumatology

Atrial fibrillation

downin mice1

1 study
  1. Dasatinib + quercetin lowers the risk of atrial fibrillation in irradiated mice.

    “a marked reduced susceptibility to AF”

    Animalsin irradiated mice

    Radiation-induced atrial fibrillation is driven by cellular senescence via the GATA4 - NF-κB pathway and rescued by D/Q senolytic therapy

    International immunopharmacology

More on Atrial fibrillation

Immune response

mixedin reviews1

1 study
  1. Senolytics are associated with immune response.

    “senotherapies reshape immune landscapes and how immunotherapies impact senescent cell burden and function”

    Review

    The senescence-immune axis as a target for combining immunotherapy and senotherapy

    Ageing research reviews

More on Immune response

Gene expression and protein expression

mixedin human cells1

1 study
  1. Dasatinib + quercetin is associated with gene expression and protein expression in human cells (senescent human mesenchymal stem cell populations).

    “Senolytic-treated populations showed inconsistent results in osteogenic and adipogenic differentiation, gene expression and protein expression.”

    Cellssenescent human mesenchymal stem cell populations

    Combined senolytics induce varied phenotypic and functional responses on senescent phenotypes of mesenchymal stromal cell populations

    Biochimie

More on Gene expression and protein expression

osteogenic and adipogenic differentiation

mixedin human cells1

1 study
  1. Dasatinib + quercetin is associated with osteogenic and adipogenic differentiation in human cells (senescent human mesenchymal stem cell populations).

    “Senolytic-treated populations showed inconsistent results in osteogenic and adipogenic differentiation, gene expression and protein expression.”

    Cellssenescent human mesenchymal stem cell populations

    Combined senolytics induce varied phenotypic and functional responses on senescent phenotypes of mesenchymal stromal cell populations

    Biochimie

Senescence and SASP biomarkers

mixedin humans1

1 study
  1. Fisetin is associated with senescence and SASP biomarkers in humans.

    “potential of fisetin and quercetin to modulate senescence and SASP biomarkers in animal models of aging and progeria, as well as in interventional studies involving human subjects”

    Review

    Exploring the Senotherapeutic Potential of Polyphenols in Aging and Disease: A Literature Review

    International journal of molecular sciences

More on Senescence and SASP biomarkers

CD8 T cell immunodominance

mixedin mice1

1 study
  1. Dasatinib + quercetin is associated with CD8 T cell immunodominance in mice (vaccinated aged mice during infection).

    “we observed altered CD8 T cell immunodominance”

    Animalsvaccinated aged mice during infection

    Senolytic Treatment With Dasatinib and Quercetin Reshapes Influenza-Specific CD8 T Cell Responses During Infection in Aged, Vaccinated Mice

    Aging cell

Cancer-related microRNA expression

mixedin human cells1

1 study
  1. Fisetin is associated with cancer-related microRNA expression in colon cancer cell lines.

    “We identified three phytochemicals (fisetin, glabridin, and silibinin) that suppressed cell proliferation and were associated with changes in cancer-related miRNA expression in colon cancer cells.”

    Cellsin colon cancer cell lines

    Discovering Anticancer Effects of Phytochemicals on MicroRNA in the Context of Data Mining

    Nutrients

More on Cancer-related microRNA expression

Biomaterials

upin reviews1

1 study
  1. Biomaterials are associated with senolytics.

    “materials as delivery systems for senolytics or as platforms that modulate immune clearance”

    Review

    Biomaterials targeting senescent cells for bone regeneration: State-of-the-art and future perspectives

    Bioactive materials

More on Biomaterials

Anti-tumor therapies

no changein reviews1

1 study
  1. Senolytics are associated with anti-tumor therapies.

    “most senolytic drugs are repurposed from existing anti-tumor therapies”

    Review

    Unraveling the meta-hallmarks between senescent and tumor cells: A new perspective for senolytic drug discovery

    Acta pharmaceutica Sinica. B

More on Anti-tumor therapies

Lipid profile

mixedin humans1

1 study
  1. Dasatinib + quercetin is associated with lipid profile in humans (modest).

    “Mass spectrometry indicated stable levels of amyloid β and tau proteins in CSF, unchanged urinary metabolites, and modest treatment-associated lipid profile changes”

    Human trialn = 5

    Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer's disease

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

More on Lipid profile

All 12

Trials

25 of 25 about aging

Who is developing senolytics?

2 companies: AbbVie and Unity Biotechnology.

Companies
  • AbbVienavitoclaxPhase 3myelofibrosis, cd20 positive lymphoid malignancy
  • Unity Biotechnologyubx1325Phase 2neovascular age-related macular degeneration, diabetic macular edema

Trial sponsors

Funding

78 grants since 2018

National Institute on Aging$15MJapan Society for the Promotion of Science¥239MNational Institute of Arthritis and Musculoskeletal and Skin Diseases$3.4M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Preprints report that fisetin extends worm lifespan; independent labs reproduce reduced senescence with dasatinib plus quercetin in human cells. Mouse studies of experimental autoimmune encephalomyelitis report improved survival but also unchanged clinical outcomes with dasatinib plus quercetin. Nineteen registered trials concern aging; Unity Biotechnology sponsors one, and some papers declare company ties.

  2. Summary rewritten as its findings changed.

    As it read before

    Independent labs reproduce senescence-marker reductions in cells and mice; a human trial reports fibrotic MASH resolution, with human work from one group. Mouse immune-response results include activation and no effect; frailty increases in rTg4510 mice. Twelve of 65 trials lack results over a year after ending; five findings declare maker interests, and AbbVie and Genentech sponsor 17 trials.

  3. Summary rewritten as its findings changed.

    As it read before

    In a human trial of fibrotic MASH, dasatinib plus quercetin clears liver senescence, reduces fibrosis, and promotes disease resolution. Cellular, zebrafish, and mouse studies further show senolytics suppress senescence markers, senescent cells, and pathogenic immune phenotypes.

  4. Summary written from the findings.

Latest

bioRxiv

Protein levels alter drug sensitivity in lab-grown human cells

Cells still stopped dividing after radiation, but protein levels changed their secreted signals and sensitivity to a drug that kills senescent cells.Cells still stopped dividing after radiation, but protein levels changed their secreted signals and sensitivity to a drug that kills senescent cells.

Preprint: human cell studyMechanisms
Neuro-Oncology

Older mice had shorter survival with human brain tumors

Median survival after human glioblastoma implantation was 40 days in young mice, compared with 33 days in older mice.Median survival after human glioblastoma implantation was 40 days in young mice, compared with 33 days in older mice.

Mouse studyInterventions
NPJ Aging

Skin cells that stopped dividing promoted melanoma growth in mice

Animal experiments found that aging and chronic ultraviolet B exposure changed the skin environment in ways that favored tumor growth.Animal experiments found that aging and chronic ultraviolet B exposure changed the skin environment in ways that favored tumor growth.

Mouse studySkin
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration

Two drugs improved thinking and muscle function in mice

Quercetin and dasatinib improved thinking and muscle function in genetically modified mice used to model amyotrophic lateral sclerosis, a disease affecting movement.Quercetin and dasatinib improved thinking and muscle function in genetically modified mice used to model amyotrophic lateral sclerosis, a disease affecting movement.

Mouse studyMuscle

See all 2,791 papers on senolytics